AMAG Pharmaceuticals AMAG today announced that the Swiss
Agency for Therapeutic Products (Swissmedic) has granted marketing
authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy
to treat iron deficiency anemia (IDA) in adult patients with chronic kidney
disease (CKD). Ferumoxytol was approved for the same indication in the
European Union in June 2012, and in the United States and Canada under the
brand name Feraheme® in June 2009 and December 2011, respectively.
AMAG's partner, Takeda Pharmaceutical Company Limited, is responsible for
commercialization of ferumoxytol in Switzerland, the EU and Canada, among
other territories. Takeda plans to launch ferumoxytol in Switzerland under the
brand name Rienso®. AMAG is entitled to receive tiered, double-digit royalties
on product sales in the licensed territories. AMAG has sole commercial rights
for Feraheme in the United States.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in